SMS Lifesciences , now known as Haleos Labs Limited, has reported its financial results for the second quarter of fiscal year 2026, showing a decline in both revenue and profit compared to the same period last year.

Key Financial Highlights

• Net Profit: Rs 497.77 lakhs for Q2 FY2026, down 17.15% from Rs 600.83 lakhs in Q2 FY2025
• Revenue from Operations: Rs 7,784.38 lakhs, a slight decrease of 0.83% from Rs 7,849.62 lakhs year-over-year
• Basic Earnings Per Share: Rs 16.46, compared to Rs 19.87 in the corresponding quarter of the previous year

Half-Year Performance

For the first half of FY2026, Haleos Labs reported:

• Net Profit: Rs 1,013.54 lakhs, down 18.71% from Rs 1,246.82 lakhs in H1 FY2025
• Revenue: Rs 15,688.63 lakhs, a decrease of 4.96% from Rs 16,506.68 lakhs in the previous year

Financial Position

The company's balance sheet as of September 30, 2025, shows:

Business Overview

Haleos Labs Limited, which officially changed its name from SMS Lifesciences India Limited on August 21, 2025, is a pharmaceutical company specializing in the manufacture of Active Pharmaceutical Ingredients (APIs) and their intermediates.

Management Commentary

The financial statements were approved by the Board of Directors at their meeting held on November 10, 2025, after being reviewed and recommended by the Audit Committee.

Auditor's Review

The statutory auditors, CA Rambabu & Co., have carried out a limited review of the financial results for the quarter and half-year ended September 30, 2025, and have expressed an unmodified opinion.

Conclusion

Haleos Labs Limited has experienced a decline in both revenue and profit for Q2 FY2026 compared to the same period last year, while maintaining a strong balance sheet. The recent change in the company's name may indicate a new strategic direction, although no specific details have been provided regarding future plans or the reasons behind the current financial performance.

SMS Lifesciences Limited, also known as Haleos Labs Limited, has announced a temporary withholding of dividend payments for certain shareholders. This decision comes in the wake of incomplete Know Your Customer (KYC) details and incorrect bank account information for some investors.

Dividend Details

The company approved a dividend of 15% (₹1.50 per equity share of ₹10 each) for the financial year 2024-25 at their 19th Annual General Meeting held on September 30, 2025. The record date for this dividend was set as September 24, 2025.

Reasons for Dividend Withholding

The dividend payments have been withheld for shareholders due to:

1. Non-updation of KYC details, including:
   • PAN (Permanent Account Number)
   • Address
   • Email ID
   • Mobile number
   • Bank mandate
2. Rejection of dividend payments by banks due to incorrect bank account details

Communication to Affected Shareholders

SMS Lifesciences has taken proactive steps to address this issue:

• Individual letters were sent to affected shareholders on November 6, 2025
• Shareholders were informed that dividends will be released only upon compliance with KYC requirements as per SEBI regulations

Action Required from Shareholders

Shareholders need to take the following actions to receive their dividends:

1. For Physical Shareholders: Submit required documents to the company's Registrar and Share Transfer Agent, Aarthi Consultants Private Limited

2. For Electronic Shareholders: Update details with their Depository Participant

Document Requirements for Physical Shareholders

SMS Lifesciences has emphasized that upon receipt and verification of updated details, the withheld dividends will be released to the registered bank accounts of the shareholders.

This move by SMS Lifesciences aligns with the SEBI circular dated December 31, 2024, and underscores the importance of maintaining up-to-date KYC information for smooth financial transactions in the stock market.